Current Progress and Future With Glembatumumab Vedotin in TNBC

Clinical implications of progress in TNBC therapiesПодробнее

Antibody-Drug Conjugates for TNBCПодробнее

The importance of a biomarker-directed approach in triple-negative breast cancerПодробнее

Future of genomics in breast cancer careПодробнее

Future Directions for Treatment of TNBCПодробнее

Current treatment landscape of triple negative breast cancerПодробнее

Treatment Planning for Triple Negative Breast Cancer | 2022 Evolution ConferenceПодробнее

Potential for Glembatumumab Vedotin in TNBCПодробнее

Investigational Strategies and the Future of TNBCПодробнее

Current status and future perspectives in immunotherapy for glioblastomaПодробнее

Future role of genomic tools in breast cancer treatmentПодробнее

New Developments in Triple-Negative Breast Cancer Therapies - Medpage TodayПодробнее

Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355Подробнее

Triple Negative Breast Cancer: Predictive and Prognostic Biomarkers for Neo/Adjuvant TherapyПодробнее

Dr. Finn on Current Research in Triple-Negative Breast CancerПодробнее

Estimating Outcomes in Triple Negative Breast CancerПодробнее

Immunological signatures to predict outcomes in patients with TNBCПодробнее

Case 3: Treatment After Progression in Triple-Negative Breast CancerПодробнее

Dr. Tolaney on Platinum-Based Therapy in Neoadjuvant Setting of TNBCПодробнее